Advertisement

Topics

CMS Explains “Newness” Criterion In Blincyto NTAP Discontinuation

11:13 EDT 21 Aug 2017 | SCRIP

Amgen’s argument that continuing the Medicare new technology add-on payment for Blincyto would allow for more data to be collected...

      

Related Stories

 

Original Article: CMS Explains “Newness” Criterion In Blincyto NTAP Discontinuation

NEXT ARTICLE

More From BioPortfolio on "CMS Explains “Newness” Criterion In Blincyto NTAP Discontinuation"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...